Clinical trials: Ulcerative Colitis, Active Moderate
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
- Trial name
- EMERALD-3 (NCT07415044)
- Testing
- LY4268989
- Where
- 258 sites in United States, Argentina and 26 more
- Volunteers
- 1,431 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
This is a randomized, double blind, placebo-controlled, parallel group multi-center study in adult participants with active moderate to severe UC.
- Trial name
- NCT01671956
- Testing
- Bertilimumab
- Where
- 6 sites in Israel
- Volunteers
- 32 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment
The study will evaluate the effectiveness, safety and tolerability of tacrolimus lipid suspension for enema in adult patients with mild to moderately active ulcerative colitis who had an inadequate response or intolerance of at…
- Trial name
- NCT06867042
- Testing
- Tacrolimus Lipid Suspension for enema, Identical Tacrolimus-free Lipid Suspension for Enema
- Volunteers
- 150 people
- Sponsor
- Jina Pharmaceuticals Inc.
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
TD-1473 for Active Ulcerative Colitis (UC)
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TD-1473 in subjects with moderately-to-severely active UC over 28 days.
- Trial name
- NCT02818686
- Testing
- TD-1473
- Where
- 8 sites in United States, Georgia and 2 more
- Volunteers
- 40 people
- Sponsor
- Theravance Biopharma
Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single-dose TD-3504 and single dose 15N2-tofacitinib in healthy subjects and subjects with UC.
- Trial name
- NCT03103412
- Testing
- TD-3504, 15N2-tofacitinib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Moderate Active Ulcerative Colitis
Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis
This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of E6007 once daily for 8 weeks in Japanese participants with moderate active ulcerative colitis.
- Trial name
- NCT03018054
- Testing
- E6007
- Where
- 64 sites in Japan
- Volunteers
- 147 people
- Sponsor
- EA Pharma Co., Ltd.
Ulcerative Colitis, Active Moderate
Adacolumn in Refractory UC Patients Trial
The objectives of the study are to observe and document the efficacy and safety of 5 or more Adacolumn treatments, administered once weekly over 5 or more weeks, in a specific subset of ulcerative colitis patients.
- Trial name
- ART (NCT01481142)
- Testing
- (GMA) Adsorptive Apheresis
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd